April 13, 2018 / 1:05 PM / 7 months ago

BRIEF-Kalytera Terminates Pre Clinical Programs In Bone Disease

April 13 (Reuters) - Kalytera Therapeutics Inc:

* COMPANY TO FOCUS RESOURCES ON GVHD AND PAIN PROGRAMS

* DETERMINED INVESTMENTS OF TIME, RESOURCES IN THESE PROGRAMS NOT APPROPRIATE GIVEN OTHER OPPORTUNITIES IN DEVELOPMENT PIPELINE

* TERMINATED PROGRAMS WERE EVALUATING THREE SYNTHETIC ENDOCANNABINOID COMPOUNDS, KAL436, KAL439 AND KAL671

* CLINICAL PROGRAMS DOES NOT REFLECT A NEGATIVE ASSESSMENT OF COMPOUNDS LICENSED FROM YISSUM

* DECISION TO TERMINATE THESE PROGRAMS IS PART OF OVERALL STRATEGY TO FOCUS ON DEVELOPMENT OF CANNABINOID THERAPEUTICS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below